Serina Therapeutics annual free cash flow
2017
2018
2019
2020
2023
2024
2025
Serina Therapeutics Free Cash Flow (FCF) History (SER)
Serina Therapeutics reported −$18.0M in free cash flow for fiscal 2025, a decrease of $855,000 from the previous fiscal year, with a free cash flow margin of −13856.92%.
View full Serina Therapeutics company overviewSerina Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$18.0M | −$855,000 | — | −13856.92% |
| 2024 | 2024-12-31 | −$17.2M | −$14.2M | — | −30641.07% |
| 2023 | 2023-12-31 | −$3.0M | $4.9M | — | −94.51% |
| 2020 | 2020-12-31 | −$7.8M | $3.0M | — | −2170.91% |
| 2019 | 2019-12-31 | −$10.8M | −$2.8M | — | −625.06% |
| 2018 | 2018-12-31 | −$8.0M | −$1.7M | — | −574.21% |
| 2017 | 2017-12-31 | −$6.3M | — | — | −447.72% |
Serina Therapeutics quarterly free cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$6.7M | −$2.9M | — | — |
| Q1 2026 | 2026-03-31 | −$4.6M | −$271,000 | — | — |
| Q4 2025 | 2025-12-31 | −$6.0M | −$1.4M | — | — |
| Q3 2025 | 2025-09-30 | −$3.9M | −$898,000 | — | — |
| Q2 2025 | 2025-06-30 | −$3.8M | $4.2M | — | −2920.00% |
| Q1 2025 | 2025-03-31 | −$4.3M | −$2.7M | — | — |
| Q4 2024 | 2024-12-31 | −$4.6M | −$3.5M | — | — |
| Q3 2024 | 2024-09-30 | −$3.0M | −$1.3M | — | −21178.57% |
| Q2 2024 | 2024-06-30 | −$8.0M | −$6.1M | — | −15703.92% |
| Q1 2024 | 2024-03-31 | −$1.6M | $657,000 | — | −31820.00% |
| Q3 2023 | 2023-09-30 | −$1.1M | $925,000 | — | −3941.38% |
| Q4 2020 | 2020-12-31 | −$1.6M | $1.1M | — | −1025.32% |
| Q3 2020 | 2020-09-30 | −$1.9M | $708,000 | — | −2755.07% |
| Q2 2020 | 2020-06-30 | −$2.2M | $617,000 | — | −4995.56% |
| Q1 2020 | 2020-03-31 | −$2.1M | $553,000 | — | −2323.60% |
| Q4 2019 | 2019-12-31 | −$2.7M | −$660,000 | — | −492.90% |
| Q3 2019 | 2019-09-30 | −$2.6M | −$818,000 | — | −634.79% |
| Q2 2019 | 2019-06-30 | −$2.9M | −$692,000 | — | −753.95% |
| Q1 2019 | 2019-03-31 | −$2.6M | −$615,000 | — | −675.52% |
| Q4 2018 | 2018-12-31 | −$2.0M | — | — | −653.67% |
| Q3 2018 | 2018-09-30 | −$1.8M | — | — | −471.32% |
| Q2 2018 | 2018-06-30 | −$2.2M | — | — | −468.32% |
| Q1 2018 | 2018-03-31 | −$2.0M | — | — | −839.33% |
Serina Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$8.0M to −$18.0M, a net decrease of $10.0M. Serina Therapeutics's latest reported quarter, Q2 2026, generated −$6.7M in free cash flow, a decrease of $2.9M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Serina Therapeutics filings at SEC.gov ↗